HIGH EXPRESSION OF C-MET WITH WIDE TYPE EGFR MUTATION IDENTIFY A DISTINCT SUBSETS INDICATIVE POOR PROGNOSIS IN PATIENTS WITH NSCLC

被引：0
|
作者：
Huang, Ling [1 ]
An, She J. [1 ]
Chen, Zhi H. [1 ]
Su, Jian [1 ]
Xie, Zhi [1 ]
Yan, Hong H. [1 ]
Zhang, Xu C. [1 ]
Huang, Ying [1 ]
Chen, Shi L. [1 ]
Guo, Wei B. [1 ]
Wu, Yi-long [1 ]
机构：
[1] Guangdong Acad Med Sci, Guangdong Gen Hosp, Guangdong Lung Canc Inst, Pulm Oncol, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2012年 / 7卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-050
引用
收藏
页码：S470 / S470
页数：1
相关论文
共 50 条
  • [41] c-Met Expression Is a Marker of Poor Prognosis in Patients With Locally Advanced Head-and-Neck Squamous Cell Carcinoma Treated With Chemoradiation Molecular Biology and Therapeutics
    Baschnagel, A. M.
    Williams, L.
    Hanna, A.
    Chen, P. Y.
    Krauss, D. J.
    Pruetz, B.
    Akervall, J.
    Wilson, G. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 88 (02): : 469 - 469
  • [42] TP53 Mutations are Present in Targeted NGS Profiles from EGFR Wild type, NSCLC Patients with Poor Prognosis
    Mellet, H.
    Jackson, L.
    Hahn, W.
    Dupuis, N.
    Weaver, A.
    Greer, J.
    Pestano, G.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2016, 18 (06): : 1012 - 1012
  • [43] Expression of β-Catenin, MUC1 and c-Met in Diffuse-type Gastric Carcinomas: Correlations with Tumour Progression and Prognosis
    Retterspitz, Monika F.
    Moenig, Stefan P.
    Schreckenberg, Stephanie
    Schneider, Paul M.
    Hoelscher, Arnulf H.
    Dienes, Hans P.
    Baldus, Stephan E.
    ANTICANCER RESEARCH, 2010, 30 (11) : 4635 - 4641
  • [44] Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype
    Garcia, Stephane
    Dales, Jean-Philippe
    Charafe-Jauffret, Emmanuelle
    Carpentier-Meunier, Severine
    Andrac-Meyer, Lucile
    Jacquemier, Jocelyne
    Andonian, Claudine
    Lavaut, Marie-Noelle
    Allasia, Claude
    Bonnier, Pascal
    Charpin, Colette
    HUMAN PATHOLOGY, 2007, 38 (06) : 830 - 841
  • [45] p53 mutation pattern and expression of c-erbB2 and c-met in gastric cancer -: Relation to histological subtypes, Helicobacter pylori infection, and prognosis
    Kubicka, S
    Claas, C
    Staab, S
    Kühnel, F
    Zender, L
    Trautwein, C
    Wagner, S
    Rudolph, KL
    Manns, M
    DIGESTIVE DISEASES AND SCIENCES, 2002, 47 (01) : 114 - 121
  • [46] The expression of ALK, RET, ROS1, c-MET, EGFR and IGF-R1 in uveal melanoma and its association to clinicopathological characteristics and prognosis
    Proenca, Rita Pinto
    Fonseca, Cristina
    Goyeneche, Alicia Alejandra
    Ito, Hiroaki
    Dias, Ana
    Marques-Neves, Carlos
    Burnier, Miguel N.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2020, 61 (07)
  • [47] Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation
    Su, Shan
    Dong, Zhong-Yi
    Xie, Zhi
    Yan, Li-Xu
    Li, Yu-Fa
    Su, Jian
    Liu, Si-Yang
    Yin, Kai
    Chen, Rui-Lian
    Huang, Shu-Mei
    Chen, Zhi-Hong
    Yang, Jin-Ji
    Tu, Hai-Yan
    Zhou, Qing
    Zhong, Wen-Zhao
    Zhang, Xu-Chao
    Wu, Yi-Long
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (11) : 1668 - 1675
  • [48] p53 Mutation Pattern and Expression of c-erbB2 and c-met in Gastric Cancer: Relation to Histological Subtypes, Helicobacter pylori Infection, and Prognosis
    Stefan Kubicka
    Christiane Claas
    Sven Staab
    Florian Kühnel
    Lars Zender
    Christian Trautwein
    Siegfried Wagner
    Karl Lenhard Rudolph
    Michael Manns
    Digestive Diseases and Sciences, 2002, 47 : 114 - 121
  • [49] Expression of beta-catenin, C-Met and MUC1 in diffuse-type-gastric carcinomas: Correlations with tumor progression and prognosis
    Retterspitz, M. F.
    Monig, S. P.
    Holscher, A. H.
    Dienes, H. P.
    Baldus, S. E.
    ONKOLOGIE, 2008, 31 : 91 - 92
  • [50] A phase III global study of telisotuzumab vedotin versus docetaxel in previously treated patients with c-Met overexpressing, EGFR wildtype, locally advanced/metastatic nonsquamous NSCLC (TeliMET NSCLC-01)
    Lugini, A.
    Goldman, J. W.
    Tanizaki, J.
    Akamatsu, H.
    Xia, S.
    Ratajczak, C.
    Li, M.
    Bolotin, E.
    Seraj, J.
    Lu, S.
    ANNALS OF ONCOLOGY, 2023, 34
12345